Notably, we demonstrate that the FDA-approved drug RTA-408 acted as a potent inhibitor of KLHL37, which disrupted the KLHL37–N-Myc interaction to facilitate the rapid degradation of N-Myc and neuroblastoma inhibition. The gene discussed is MYCN; the disease is neuroblastoma.